慢性粒细胞白血病治疗中关于停药及治愈问题的研究进展：第54届美国血液学会年会报道

Report on discontinuation of tyrosine kinase inhibitor therapy and the cure of chronic myelogenous leukemia in the 54th ASH annual meeting

伊马替尼（IM）及其他酪氨酸激酶抑制剂（TKI）在临床应用中的巨大成功，使慢性粒细胞白血病（CML）的治疗走在肿瘤靶向治疗的前沿。尽管TKI的出现极大地改善了CML患者的预后，然而长期TKI治疗可能给患者带来耐药、严重不良反应、依从性差、沉重的经济负担等问题。近年来，关于CML患者在达到长期完全分子生物学缓解（CMR）后能否安全停药及停药后能否达到治愈是CML研究中的关注点。就2012年第54届美国血液学会（ASH）年会关于CML患者停药及治愈问题的研究进展进行报道。

With the great success of imatinib mesylate（IM） and other tyrosine kinase inhibitor （TKI）, chronic myelogenous leukemia （CML） is taken as a successful model of targeted therapies for human cancer. Although the emergence of TKI has greatly improved the prognosis of CML, the long-term TKI treatment may bring the problems of drug resistance, serious side effects, poor compliance, and heavy economic burden. Recently, people focus on whether patients would be cured after discontinuation of TKI treatment. Here, the progresses on discontinuation of TKI therapy in CML presented in the 54th American Society of Hematology （ASH） annual meeting were reviewed.